Alefacept for the treatment of psoriasis: A review of the current literature and practical suggestions for everyday clinical use

Seminars in Cutaneous Medicine and Surgery

Volumn 24, Issue 1, 2005, Pages 10-18

  Korman, Neil J ^a,b   Moul, Danielle K ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIBIOTIC AGENT; ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; HYBRID PROTEIN; METHOTREXATE; RETINOID; STEROID; TETANUS TOXOID; VITAMIN D DERIVATIVE;

ANTIBODY PRODUCTION; BIRTH DEFECT; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DECISION MAKING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENZYME BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNIZATION; INFECTION; INFLAMMATION; INJECTION PAIN; INJECTION SITE REACTION; MELANOMA; MEMORY CELL; MONITORING; MULTICENTER STUDY; PATIENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; POPULATION RESEARCH; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SKIN CANCER; T LYMPHOCYTE ACTIVATION; UNITED STATES;

BIOLOGICAL PRODUCTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; PSORIASIS; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY; UNITED STATES;

EID: 15744363738     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2005.01.001     Document Type: Review

References (36)

1. G. Krueger, J. Koo, M. Lebwohl The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
2. M.A. Gupta, A.K. Gupta Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis Br J Dermatol 139 1998 846 850
3. G.D. Weinstein, A.B. Gottlieb Therapy of Moderate-to-Severe Psoriasis (ed 2) 2003 M. Dekker New York 91 178
4. J.G. Kreuger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23
5. J.D. Bos, C. Hagenaars, P.K. Das Predominance of "memory" T cells (CD4, CDw29+) over "naïve" T cells (CD4+, CD45R+) in both normal and diseased human skin Arch Dermatol Res 281 1989 24 30
6. G.S. Morganroth, L.S. Chan, G.D. Weinstein Proliferating cells in psoriatic dermis are comprised primarily of T-cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells J Invest Dermatol 96 1991 333 340
7. P.L. Chisholm, C.A. William, W.E. Jones The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates Ther Immunol 1 1994 205 216
8. W. Meier, A. Gill, M. Rogge Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein cell line dependent glycosylation effects on pharmokinetics and pharmacodynamic markers Ther Immunol 2 1995 159 171
9. G.R. Majeu, W. Meier, B. Jimmo Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses Structure/function analysis in vitro and in human CD2 transgenic mice J Immunol 152 1994 2753 2767
10. R.J. Kaplon, P.S. Hochman, R.E. Michler Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival Transplantation 61 1996 356 363
11. G.T. Miller, P.S. Hochman, W. Meier Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T cell responses J Exp Med 178 1993 211 222
12. A.K. Vaishnaw, C.N. TenHoor Pharmacokinetics, Biologic Activity and Tolerability of Alefacept by Intravenous and Intramuscular Administration J Pharmacokinet Pharmacodyn 29 2002 415 426
13. C.N. Ellis, G.G. Krueger Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255
14. G.G. Krueger, C.N. Ellis Alefacept therapy produces remission for patients with chronic plaque psoriasis Br J Dermatol 148 2003 784 788
15. C.N. Ellis, M.M. Mordin, E.Y. Adler Effects of alefacept on health-related quality of life in patients with psoriasis Results from a randomized, placebo-controlled phase II trial Am J Clin Dermatol 4 2003 131 139
16. N.J. Lowe, J. Gonzalez, J. Bagel Repeat Courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy Int J Dermatol 42 2003 224 230
17. G.G. Krueger, K.A. Papp, D.B. Stough A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833
18. G.G. Krueger Clinical response to alefacept results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis J Eur Acad Dermatol Venerol 17 suppl 2 2003 17 24
19. K.B. Gordon, A.K. Vaishnaw, J. O'Gorman Treatment of psoriasis with alefacept correlation of clinical improvement with reductions of memory T-cell counts Arch Dermatol 139 2003 1563 1570
20. S.R. Feldman, J.Y. Menter A Koo Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis Br J Dermatol 150 2004 317 326
21. M. Lebwohl, E. Christophers, R. Langley An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727
22. J.P. Ortonne Clinical response to alefacept Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis J Eur Acad Dermatol Venereol 17 suppl 2 2003 12 16
23. K.B. Gordon, R.G. Langley Remittive effects of intramuscular alefacept in psoriasis J Drugs Dermatol 2 2003 624 628 6
24. A.Y. Finlay, M.S. Salek, J. Haney Alefacept Clinical Study Group Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis Dermatology 206 2003 307 315
25. J.P. Ortonne, M. Lebwohl, C.E. Griffiths Alefacept Clinical Study Group Alefacept-induced decreases in circulating blood lymphocytes counts correlate with clinical response in patients with chronic plaque psoriasis Eur J Dermatol 13 2003 117 123
26. A.B. Gottlieb, T.B. Casale, E. Frankel CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept Results of randomized study J Am Acad Dermatol 49 2003 816 825
27. Biogen Idec. Amevive (Alefacept) Briefing Document. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting. Available at: www.fda.gov/ohrms/ dockets/ac/02/briefing/3865B1_01_Biogen.pdf ; Internet; accessed January 26, 2005
28. C.H. Gribetz, R. Blum, C. Brady The effect of 16 weeks of alefacept compared with 12 weeks of alefacept in the treatment of chronic plaque psoriasis 2004 Poster presented at the International Psoriasis Symposium June 10-13, (abstr)
29. nd Annual Meeting of American Academy of Dermatology Feb 6-11, (abstr)
30. J. Koo Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis 2003 Poster presented at the International Psoriasis Symposium June 18-22, (abstr)
31. J.P. Otronne, A. Kehmis Combination therapy with alefacept plus narrowband ultraviolet B light for treatment of psoriasis 2003 Poster presented at the International Psoriasis Symposium June 18-22, (abstr)
32. A. Menter, W. Abramovits, J.C. Cather Transitioning patients with psoriasis from methotrexate to alefacept 2004 Poster presented at the International Psoriasis Symposium June 10-13, (abstr)
33. M. Magliocco, A.M. Lozano, C. Kipnis Transitioning patients with psoriasis from cyclosporine to alefacept therapy results of an open-label study 2004 Poster presented at the American Academy of Dermatology Meeting July 28-August 1, (abstr)
34. A. Menter, J.C. Cather, D. Baker, H.F. Farber, M. Lebwohl Long-term Use of Alefacept efficacy in patients who have received multiple courses of therapy 2005 Poster Presented at the 63rd Annual Meeting of the American Academy of Dermatology Meeting February 18-22, (abstr)
35. nd Annual Meeting of American Academy of Dermatology Feb 6-11, (abstr)
36. nd Annual Meeting of the American Academy of Dermatology Feb 6-11, (abstr)